|
[1]EL-SERAG HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J].Gastroenterology, 2012, 142 (6) :1264-1273.
|
|
[2]TORRE LA, BRAY F, SIEGEL RL, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.
|
|
[3]GARCIA-TSAO G, FRIEDMAN S, IREDALE J, et al.Now there are many (stages) where before there was one:in search of a pathophysiological classification of cirrhosis[J].Hepatology, 2010, 51 (4) :1445-1449.
|
|
[4]AUGUSTIN S, PONS M, MAURICE JB, et al.Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease[J].Hepatology, 2017, 66 (6) :1980-1988.
|
|
[5]de FRANCHIS R, Baveno VI Faculty.Expanding consensus in portal hypertension:report of the Baveno VI Consensus Workshop:stratifying risk and individualizing care for portal hypertension[J].J Hepatol, 2015, 63 (3) :743-752.
|
|
[6]CHANG TT, LIAW YF, WU SS, et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology, 2010, 52 (3) :886-893.
|
|
[7]WONG GL, CHAN HL, MAK CW, et al.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis[J].Hepatology, 2013, 58 (5) :1537-1547.
|
|
[8]BEDOSSA P, DARGERE D, PARADIS V.Sampling variability of liver fibrosis in chronic hepatitis C[J].Hepatology, 2003, 38 (6) :1449-1457.
|
|
[9]TAPPER EB, CASTERA L, AFDHAL NH.Fibro Scan (vibration-controlled transient elastography) :where does it stand in the United States practice[J].Clin Gastroenterol Hepatol, 2015, 13 (1) :27-36.
|
|
[10]LIM JK, FLAMM SL, SINGH S, et al.American Gastroenterological Association Institute Guideline on the role of elastography in the evaluation of liver fibrosis[J].Gastroenterology, 2017, 152 (6) :1536-1543.
|
|
[11]SHIHA G, IBRAHIM A, HELMY A, et al.Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis:a 2016update[J].Hepatol Int, 2017, 11 (1) :1-30.
|
|
[12]FRIEDRICH-RUST M, POYNARD T, CASTERA L.Critical comparison of elastography methods to assess chronic liver disease[J].Nat Rev Gastroenterol Hepatol, 2016, 13 (7) :402-411.
|
|
[13]TOROK NJ, DRANOFF JA, SCHUPPAN D, et al.Strategies and endpoints of antifibrotic drug trials:summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014[J].Hepatology, 2015, 62 (2) :627-634.
|
|
[14]WANG Y, LIANG X, YANG J, et al.Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of non-advanced liver fibrosis for chronic hepatitis B[J].J Viral Hepat, 2017.[Epub ahead of print]
|
|
[15]WANG Y, VINCENT R, YANG J, et al.Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis[J].Hepatology, 2017, 65 (6) :1891-1903.
|
|
[16] GE PS, RUNYON BA.Treatment of patients with cirrhosis[J].N Engl J Med, 2016, 375 (8) :767-777.
|
|
[17]ROCKEY DC.Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies[J].Clin Gastroenterol Hepatol, 2013, 11 (3) :224-231.
|
|
[18]FRIEDMAN SL, RATZIU V, HARRISON SA, et al.A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J].Hepatology, 2017.[Epub ahead of print]
|
|
[19]TRAUTWEIN C, FRIEDMAN SL, SCHUPPAN D, et al.Hepatic fibrosis:concept to treatment[J].J Hepatol, 2015, 62 (1 Suppl) :s15-s24.
|
|
[20]HIGASHI T, FRIEDMAN SL, HOSHIDA Y.Hepatic stellate cells as key target in liver fibrosis[J].Adv Drug Deliv Rev, 2017, 121:27-42.
|
|
[21]IKENAGA N, PENG ZW, VAID KA, et al.Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal[J].Gut, 2017, 66 (9) :1697-1708.
|
|
[22]LIU P, HU YY, LIU C, et al.Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B[J].World J Gastroenterol, 2005, 11 (19) :2892-2899.
|
DownLoad: